Vaccination with a nanoparticle E7 vaccine can prevent tumor recurrence following surgery in a human papillomavirus head and neck cancer model

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–6. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6:92.
   PubMed Web of Science ®Google Scholar
• Marur S, D’Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010;11(8):781–789. doi:10.1016/S1470-2045(10)70017-6.
   PubMed Web of Science ®Google Scholar
• Taberna M, Mena M, Pavon MA, Alemany L, Gillison ML, Mesia R. Human papillomavirus-related oropharyngeal cancer. Ann Oncol. 2017;28(10):2386–2398. doi:10.1093/annonc/mdx304.
   PubMed Web of Science ®Google Scholar
• Zur Hausen H. Papillomaviruses and cancer: form basic studies to clinical application. Nat Rev Cancer. 2002;5(5):342–350. doi:10.1038/nrc798.
   Web of Science ®Google Scholar
• Galliverti G, Tichet M, Domingos-Pereira S, Hauert S, Nardelli-Haefliger D, Swartz MA, et al. Nanoparticle conjugation of Human Papillomavirus 16 E7-long peptides enhances therapeutic vaccine efficacy against solid tumors in mice. Cancer Immunol Res. 2018;6(11):1301–1313. doi:10.1158/2326-6066.CIR-18-0166.
   PubMed Web of Science ®Google Scholar
• Mermod M, Hiou-Feige A, Bovay E, Roh V, Sponarova J, Bongiovanni M, et al. Mouse model of postsurgical primary tumor recurrence and regional lymph node metastasis progression in HPV-related head and neck cancer. Int J Cancer. 2018;142(12):2518–2528. doi:10.1002/ijc.31240.
   PubMed Web of Science ®Google Scholar
• Hoover AC, Spanos WC, Harris GF, Anderson ME, Klingelhutz AJ, Lee JH. The role of human papillomavirus 16 E6 in anchorage-independent and invasive growth of mouse tonsil epithelium. Archives of Otolaryngology–head & Neck Surgery. 2007;133(5):495–502. doi:10.1001/archotol.133.5.495.
   PubMedGoogle Scholar
• Van Der Burg SH, Arens R, Ossendorp F, Van Hall T, Melief CJ. Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer. 2016;16(4):219–233. doi:10.1038/nrc.2016.16.
   PubMed Web of Science ®Google Scholar
• Domingos-Pereira S, Galliverti G, Hanahan D, Nardelli-Haefliger D. Carboplatin/paclitaxel, E7-vaccination and intravaginal CpG as tri-therapy towards efficient regression of genital HPV16 tumors. J Immunother Cancer. 2019;7(1):122. doi:10.1186/s40425-019-0593-1.
   PubMed Web of Science ®Google Scholar
• Lin KY, Guarnieri FG, Staveleyocarroll KF, Levitsky HI, August JT, Pardoll DM, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class IIpresentation of tumor antigen. Cancer Res. 1996;56(1):21–26.
   PubMed Web of Science ®Google Scholar
• Simon C, Hicks MJ, Nemechek AJ, Mehta R, O’Malley BW Jr., Goepfert H, et al. PD 098059, an inhibitor of ERK1 activation, attenuates the in vivo invasiveness of head and neck squamous cell carcinoma. Br J Cancer. 1999;80(9):1412–1419. doi:10.1038/sj.bjc.6690537.
   PubMed Web of Science ®Google Scholar
• Simon C, Nemechek AJ, Boyd D, O’Malley BW Jr., Goepfert H, Flaitz CM, et al. An orthotopic floor-of-mouth cancer model allows quantification of tumor invasion. The Laryngoscope. 1998;108(11 Pt 1):1686–1691. doi:10.1097/00005537-199811000-00018.
   PubMed Web of Science ®Google Scholar
• Behren A, Kamenisch Y, Muehlen S, Flechtenmacher C, Haberkorn U, Hilber H, et al. Development of an oral cancer recurrence mouse model after surgical resection. Int J Oncol. 2010;36(4):849–855. doi:10.3892/ijo_00000562.
   PubMed Web of Science ®Google Scholar
• Revaz V, Debonneville A, Bobst M, Nardelli-Haefliger D. Monitoring of vaccine-specific gamma interferon induction in genital mucosa of mice by real-time reverse-transcription-PCR. Clin Vacc Immunol. 2008;5(5):757–764. doi:10.1128/CVI.00392-07.
   Google Scholar
• Temizoz B, Kuroda E, Ishii KJ. Vaccine adjuvants as potential cancer immunotherapeutics. Int Immunol. 2016;28(7):329–338. doi:10.1093/intimm/dxw015.
   PubMed Web of Science ®Google Scholar
• Lee DW, Anderson ME, Wu S, Lee JH. Development of an adenoviral vaccine against E6 and E7 oncoproteins to prevent growth of human papillomavirus-positive cancer. Archives of Otolaryngology–head & Neck Surgery. 2008;134(12):1316–1323. doi:10.1001/archoto.2008.507.
   PubMed Web of Science ®Google Scholar
• Dharmaraj N, Piotrowski SL, Huang C, Newton JM, Golfman LS, Hanoteau A, et al. Anti-tumor immunity induced by ectopic expression of viral antigens is transient and limited by immune escape. Oncoimmunology. 2019;8(4):e1568809. doi:10.1080/2162402X.2019.1568809.
   PubMed Web of Science ®Google Scholar
• Wang C, Dickie J, Sutavani RV, Pointer C, Thomas GJ, Savelyeva N. Targeting head and neck cancer by vaccination. Front Immunol. 2018;9:830. doi:10.3389/fimmu.2018.00830.
   PubMed Web of Science ®Google Scholar
• Market M, Baxter KE, Angka L, Kennedy MA, Auer RC. The potential for cancer immunotherapy in targeting surgery-induced natural killer cell dysfunction. Cancers. 2018;11(1):1. doi:10.3390/cancers11010002.
   PubMed Web of Science ®Google Scholar
• Chaturvedi AK, Graubard BI, Broutian T, Pickard RKL, Tong ZY, Xiao W, et al. Effect of Prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV infections among young adults in the United States. J Clin Oncol: Off J Am Soc Clin Oncol. 2018;36(3):262–267. doi:10.1200/JCO.2017.75.0141.
   PubMed Web of Science ®Google Scholar
• Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol: Off J Am Soc Clin Oncol. 2011;29(32):4294–4301. doi:10.1200/JCO.2011.36.4596.
   PubMed Web of Science ®Google Scholar
• Shewale JB, Gillison ML. Dynamic factors affecting HPV-attributable fraction for head and neck cancers. Curr Opin Virol. 2019;39:33–40. doi:10.1016/j.coviro.2019.07.008.
   PubMed Web of Science ®Google Scholar
• Harbison RA, Kubik M, Konnick EQ, Zhang Q, Lee SG, Park H, et al. The mutational landscape of recurrent versus nonrecurrent human papillomavirus-related oropharyngeal cancer. JCI Insight. 2018;3(14):14. doi:10.1172/jci.insight.99327.
   Web of Science ®Google Scholar